Jones Trading initiates Editas Medicine stock coverage with buy rating
Jones Trading initiated coverage on Editas Medicine (NASDAQ:EDIT) with a Buy rating and $8.00 price target, citing undervaluation and potential of EDIT-401 for LDL cholesterol reduction. The stock trades at $2.72. Analysts note cash burn and commercial viability challenges. Guggenheim also upgraded EDIT to Buy with a $5.00 target, citing preclinical data.
How this was made
The 30-second read
Why it matters
The new coverage could attract short‑term buying interest and raise the stock's valuation multiples.
Market read
Analyst upgrades for a low‑priced biotech provide a fresh trading catalyst.
What to watch
Potential competition from PCSK9 inhibitors and the need for regulatory approval beyond preclinical data.
Background
Editas Medicine is a micro‑cap biotech developing gene‑editing therapies for hypercholesterolemia.
Ticker impact
Jones Trading initiated coverage on Editas Medicine with a Buy rating and a new $8.00 price target.
likely upward pressure as investors price in the new buy rating and higher target.
The coverage is the first report of a buy rating and a price target above current levels, providing a fresh catalyst.
Market effects
May boost sentiment toward the gene‑editing/biotech sector as a new analyst endorsement appears.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The therapy remains unproven in humans and cash burn is high, so the buy rating could be premature.
Key entities
- analystJones Trading
Initiated coverage with a Buy rating and $8 target.
- analystGuggenheim
Also upgraded Editas to Buy with a $5 target.


